Merck’s latest investigational drug, calderasib, is not merely another entry into the burgeoning field of KRAS G12C inhibition; it represents…
Read More
Calderasib’s real innovation: designed for combinability and potency
Merck has unveiled its investigational KRAS G12C inhibitor, calderasib, positioning it not merely as another potent molecule in a rapidly…
Read More
Hugging Face Unveils ML Intern, an AI Agent Designed to Streamline Machine Learning Development
Hugging Face, a leading force in the open-source artificial intelligence community, has launched ML Intern, an innovative open-source command-line interface…
Read More
Calderasib’s Real Innovation: Designed for Combination, Not Raw Potency
Merck’s investigational KRAS G12C inhibitor, calderasib, is making headlines not for its standalone potency but for a strategically different attribute:…
Read More
Absci Secures $100 Million and Advances AI-Designed Drug Candidate ABS-201 for Endometriosis and Hair Loss
Absci Corporation has successfully closed an underwritten public offering, raising approximately $100 million, a significant financial injection that will fuel…
Read MoreYOU MAY HAVE MISSED
